Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024
Halda Therapeutics, a US biotech company advancing cancer treatments, announced the appointment of Christian Schade as president and chief executive. 1 October 2024
Nxera Pharma has entered a new commercial partnership agreement with fellow Japanese drugmaker Shionogi regarding the distribution and sales for Quviviq (daridorexant 25 and 50mg) in Japan. 1 October 2024
AstronauTx, a biotech developing novel treatments for Alzheimer's disease and other neurodegenerative disorders, has announced the appointment of Jane Rhodes as chief executive officer. 1 October 2024
Privately-held German pain specialist Grünenthal has appointed Jan Adams its new chief commercial officer (CCO) and a member of the corporate executive board. 30 September 2024
USA-based engineered regulatory T cells (Tregs) company GentiBio today announced the appointment of Dr Mark Bach as chief medical officer. 30 September 2024
Acadia Pharmaceuticals has appointed Catherine Owen Adams to succeed Steve Davis as chief executive (CEO) and a member of its board of directors. 28 September 2024
Recently-created by US biotech incubator Flagship Pioneering, Abiologics has announced the appointment of Maria-Chiara Magnone as its chief scientific officer. 26 September 2024
German privately-held biotech ARTCLINE Bio-Therapies today announced the appointment of Dirk Hessel as additional managing director of the company. 23 September 2024
Stalicla, a privately-held Swiss biotech, today announced that Dr Paulo Fontoura will be joining its drug development team as chief scientific and clinical development advisor. 19 September 2024
US contract development and manufacturing organization (CDMO) BioCentriq has appointed Syed Husain as its new chief executive (CEO), and as a member of the board of directors. 19 September 2024
Structure Therapeutics, a specialist in small molecule treatments for metabolic and pulmonary diseases, has announced key leadership appointments. 18 September 2024
Californian biopharma 89bio, a company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, has announced an important appointment. 17 September 2024
British biotech IMU Biosciences has announced key changes to its leadership team as it looks to grow in the field of precision medicine. 17 September 2024
Ohio, USA-based Trailhead Biosystems has appointed Josh Snow as its new chief commercial officer, as the company moves to expand its presence in the commercial market with its iPSC-derived human cell products. 16 September 2024
Under pressure from certain shareholders, autoimmune diseases specialist Aurinia Pharmaceuticals on Friday said it has restructured its board of directors. 14 September 2024
US neurological diseases specialist Ovid Therapeutics has announced the promotion of Meg Alexander to president and chief operating officer (COO). 12 September 2024
US-based biopharmaceutical company Nektar Therapeutics (Nasdaq: NKTR) has announced that Ivan Gergel will serve as the Company's new Senior Vice President, Drug Development & Chief Medical Officer effective immediately. 19 May 2014
US drugmaker AbbVie (NYSE: ABBV) has named Michael Severino as Executive Vice President, Research and Development (R&D) and Chief Scientific Officer. 16 May 2014
US generics major Actavis (NYSE: ACT) has announced the proposed senior management team that will lead the company pending the successful close of the acquisition of Forest Laboratories, anticipated mid-year. 14 May 2014
US biotech firm Amgen has announced the appointment of Steven Galson to the position of senior vice president, Global Regulatory Affairs and Safety, effective May 19. 14 May 2014
UK-based biopharmaceutical company Ario Pharma has announced the appointment of Professor Peter Barnes and Professor Wisia Wedzicha to its Scientific Advisory Board with immediate effect. 12 May 2014
Germany’s Merck (MRK: DE) has appointed Marcus Kuhnert as Group Chief Financial Officer. Mr Kuhnert will become a member of Merck’s Executive Board with unlimited personal liability as of August 1, 2014. 9 May 2014
US-based Eleven Biotherapeutics (Nasdaq: EBIO), a clinical-stage biopharmaceutical company developing protein therapeutics to treat eye diseases, has announced the appointment of Gary Sternberg as Executive Vice President of Corporate and Business Development. 8 May 2014
Cobra Biologics is pleased to announce the appointment of Daniel Smith as Chief Scientific Officer with the responsibility of enhancing Cobra’s DNA, virus, microbial and mammalian proteins research and development platforms. 7 May 2014
UK-based GW Pharmaceuticals has announced the appointment of Kenneth Sommerville to the newly created position of VP, Clinical Science, based in the USA. 7 May 2014
US-based pharmacogenetics company Millennium Laboratories has announced the appointment of Nikhil Nayak as chief marketing officer, Steven Soe as chief compliance officer, and Michael Flowers as vice president, government operations. 6 May 2014
Japanese drug major Astellas Pharma has announced the promotions of Bernhardt Zeiher to executive vice president, Global Development and Jeannette Barrett to vice president and head of Medical Excellence, Global Medical Affairs. 6 May 2014
UK-based cancer therapeutics firm Scancell has announced the appointment of Sally Adams to the board as Development Director with immediate effect. 1 May 2014
UK nanotechnology firm Midatech has announced the appointments of Rolf Stahel as chairman and Craig Cook as Chief Operating Officer (COO) and Chief Medical Officer (CMO). 1 May 2014
US biopharmaceutical company Coherus Biosciences has announced the appointment of Michael Fleming as senior vice president, commercial strategy. 28 April 2014